RxDoctor Payments Data

Wah Wah Htun, MD

Interventional Cardiology · la Crosse, WINPI 1083943179

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (40.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Medtronic at 54.5% of the total.

$28,355in general payments, 2019–2025

Across 108 payments — averaging $262.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$15K
  • Shockwave Medical, Inc$7K
  • Edwards Lifesciences$2K
  • Abbott$2K
  • Boston Scientific$700
  • Philips North America LLC$544
  • plus $1K from 9 others
$51,456in research payments, 2019–2025

Across 5 payments — averaging $10,291 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$29K
  • Medtronic$23K

What the payments were for

  • Consulting fees$11,36940%
  • Speaking & faculty fees$7,78827%
  • Travel & lodging$3,02111%
  • Food & beverage$6,17822%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,355 in reported general payments places this provider in the 85th percentile of 118 interventional cardiology providers in Wisconsin.

See all interventional cardiology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$313,622
Medicare patients
1,379
Services billed
3,215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban117$97,749
EntrestoSacubitril/Valsartan85$91,686
XareltoRivaroxaban27$30,353
FarxigaDapagliflozin Propanediol31$26,150
JardianceEmpagliflozin28$23,895
BrilintaTicagrelor17$15,410
Repatha SureclickEvolocumab11$7,059
Metoprolol Succinate221$3,180
Atorvastatin Calcium127$1,540
Bumetanide21$1,468
ClopidogrelClopidogrel Bisulfate77$1,265
Ezetimibe32$964
Diltiazem 24hr Er (Cd)Diltiazem Hcl44$888
Isosorbide Mononitrate ErIsosorbide Mononitrate57$717
Potassium Chloride32$585

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in la Crosse

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →